Your browser doesn't support javascript.
loading
Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Type 2 Diabetes Assessed by Retrospective Continuous Glucose Monitoring.
Zang, Li; Li, Yijun; Hao, Haojie; Liu, Jiejie; Zhang, Qian; Gao, Fei; Wang, Haibin; Chen, Yulong; Gu, Weijun; Du, Jin; Meng, Junhua; Zhang, Saichun; Lyu, Zhaohui; Dou, Jingtao; Mu, Yiming.
Afiliación
  • Zang L; Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Li Y; Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Hao H; Department of Biotherapy, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Liu J; Department of Biotherapy, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Zhang Q; Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Gao F; Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Wang H; Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Chen Y; Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Gu W; Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Du J; Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Meng J; Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Zhang S; Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Lyu Z; Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Dou J; Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Mu Y; Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Stem Cells Transl Med ; 12(12): 775-782, 2023 Dec 18.
Article en En | MEDLINE | ID: mdl-37738447
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Mesenquimatosas / Diabetes Mellitus Tipo 2 / Células Madre Mesenquimatosas Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Stem Cells Transl Med Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Mesenquimatosas / Diabetes Mellitus Tipo 2 / Células Madre Mesenquimatosas Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Stem Cells Transl Med Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido